Close Menu

NEW YORK (GenomeWeb) – Qiagen said on Thursday that it is partnering with Freenome to develop next-generation sequencing-based companion diagnostics for immuno-oncology.

Under the agreement the companies will pair Freenome's artificial intelligence genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.